Social Workers

ADHD:Systematic Review of Diagnosis and Treatment in Children and Adolescents

4.00 - CE credit hours training

$25.00 - Cost of course

This page contains important information about the course, including training details, a comprehensive course description, learning objectives, and source references. We encourage you to review each section to gain a clear understanding of the course content, educational goals, and supporting materials before beginning your training and taking the POST TEST below.

Target audience and instructional level of this course: foundational
There is no known conflict of interest or commercial support related to this CE program.

ADHD:Systematic Review of Diagnosis and Treatment in Children and Adolescents

Follow the link below, read the material and then take the 24 question post test

Read the Course Material:
ADHD:Systematic Review of Diagnosis and Treatment in Children and Adolescents

24 Questions

1. A key message of this Comparative Effectiveness Review comparing strategies to diagnose, treat and monitor children with attention deficit hyperactivity disorder (ADHD) include:
2. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) requires which of the following for a child or adolescent to be diagnosed with ADHD:
3. This Comparative Effectiveness Review, comparing strategies to diagnose, treat and monitor children with attention deficit hyperactivity disorder (ADHD) included:
4. The strength of evidence (SOE) grade when comparing pharmacological and placebo/usual care treatments in this review was insufficient because of:
5. Regarding neurofeedback as a treatment for ADHD this review found:
6. The review comparing herbal interventions or dietary strategies to diagnose, treat and monitor children with attention deficit hyperactivity disorder (ADHD) included:
7. In this review comparing strategies to diagnose, treat and monitor children with attention deficit hyperactivity disorder (ADHD) it was found that methylphenidate had slightly higher gastrointestinal effects than atomoxetine.
8. Risk factors associated with ADHD include:
9. The K-SADS (Kiddie SAFS) is a:
10. When accessing the SOE for executive function the CANTAB performed better than the ATTEX and CHEXI.
11. In this review sufficient SOE grades were found for all outcomes when assessing pharmacological versus nonpharmacologic treatments.
12. In this review the Attention and Executive Function Rating Inventory performed _______________ the Cambridge Neuropsychological Test Automated Battery for the diagnosis of ADHD for ages 7-17
13. Adverse effects from pharmacological treatment for ADHD can include:
14. In this review, when comparing different ADHD medications including atomoxetine and methphenidate the most commonly reported adverse effects were:
15. The AHRQs Methods guide for assessing Strength of Evidence (SOE) requires assessment of the following:
16. In this review, when comparing pharmacologic therapies, small numbers of studies with variable quality caused insufficient SOE grades for all outcomes except GI symptoms.
17. Regarding cognitive training studies included in the 2018 review of the treatment of ADHD:
18. The 2011 AHRQ systematic review found that adding psychosocial /behavioral interventions to psychostimulants _________________ psychosocial/behavioral interventions alone for children with ADHD and oppositional defiant disorder.
19. The DBDRS (Disruptive Behavior Disorder Rating Scale) is a:
20. The 2018 meta-analysis of treatment for ADHD looked at nutritional therapy and found:
21. Which of the following were found in this review?
22. The Connor CPT (Continuous Performance Test) assesses:
23. Questions remain about the comparative effectiveness of pharmacotherapy alone or in combination with behavioral therapy due to:
24. In this review, studies assessing child or parent training, or behavioral interventions found that ADHD symptoms were significantly improved with:
Improve your knowledge on the Diagnosis and Treatment of ADHD in Children and Adolescents with this course. Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by excessive amounts of inattention, hyperactivity, and impulsivity that are pervasive and impairing in multiple contexts. ADHD symptoms arise from executive dysfunction and emotional dysregulation is often considered a core symptom (Brown, 2008). This systematic review updates and extends two previous Agency for Healthcare Research and Quality (AHQR) systematic evidence reviews. It focuses on the comparative effectiveness of methods to establish the diagnosis of ADHD, updates the comparative effectiveness of pharmacologic and nonpharmacologic treatments, and evaluates different monitoring strategies in the primary care setting. The data sources consist of numerous relevant English-language studies published between 2011 and 2016 in PubMed, Embase, PsycINFO and the Cochrane Database of Systematic Reviews.
  1. describe the process used to evaluate the Strength of Evidence (SOE) for studies included in the 2018 Comparative Effectiveness Review Number 203 comparing strategies to diagnose, treat and monitor children with attention deficit hyperactivity disorder (ADHD).
  2. list a variety of pharmacological and non-pharmacological treatments used for children with ADHD and describe the findings for studies related to these treatments.
  3. identify key messages of the 2018 Comparative Effectiveness Review Number 203 comparing strategies to diagnose, treat and monitor children with attention deficit hyperactivity disorder (ADHD).
Click Tab on Left Prepared by the following investigators at Duke Evidence-based Practice Center Durham, NC:

Alex R. Kemper, M.D., M.P.H, M.S.
Gary R. Maslow, M.D., M.P.H.
Sherika Hill, M.H.A., Ph.D.
Behrouz Namdari, M.D.
Nancy M. Allen LaPointe, Pharm.D., M.H.S.
Adam P. Goode, D.P.T., Ph.D.
Remy R. Coeytaux, M.D., Ph.D.
Deanna Befus, B.A., B.S.N.
Andrzej S. Kosinski, Ph.D.
Samantha E. Bowen, Ph.D.
Amanda J. McBroom, Ph.D.
Kathryn R. Lallinger, M.S.L.S.
Gillian D. Sanders, Ph.D.